Amgen to acquire Horizon Therapeutics for $28.3 billionNeumann, Mark E.Nephrology News & Issues
参考: 1.https://www.amgen.com/newsroom/press-releases/2022/12/amgen-to-host-webcast-investor-call-following-announced-acquisition-of-horizon-therapeutics. 2.https://www.amgen.com/newsroom/press-releases/2022/12/rule-2-...
The proposed order also will prohibit Amgen from entering into any agreement or understanding to acquire any products or interest in any business engaged in the manufacturing or sale of any products, biosimilars, or therapeutic equivalents that treat either...
Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinica...
"We executed effectively in 2022, delivering strong volume growth, advancing numerous first-in-class medicines in our pipeline, and staying on track to achieve our long-term growth objectives," saidRobert A. Bradway, chairman and chief executive officer. "The announced acquisition of ...
AmgenHorizon Therapeutics Tristan Manalac Tristan is an independent science writer based in Metro Manila, with more than eight years of experience writing about medicine, biotech and science. He can be reached attristan.manalac@biospace.com,tristan@tristanmanalac.comor onLinkedIn. ...
Amgen to Buy Horizon Therapeutics for $28B, Edging Out Sanofi in Bidding War Sanofi submitted the first unsolicited offer to acquire Horizon Therapeutics, but Amgen ultimately won what became a competitive bidding process. Amgen says Horizon's drug lineup complements its own portfolio of autoimmune ...
5.8 percentage points to 25.1%. Non-GAAP EPS increased 13% from $4.96 to $5.58, driven by higher revenues, partially offset by higher operating expenses, including incremental expenses from Horizon, and interest expense. Non-GAAP operating income increased from $3.4 billion to $4.0 billion, and...
Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the first quarter of 2023.
or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on...